While shouldering these heavy responsibilities, pharma and biotech IP professionals must adapt to emerging challenges and take advantage of new opportunities. In recent years, the strategic landscape has changed rapidly. Not only the introduction of several important legal and legislative developments, but also a range of technological advances in the field are rewriting the life sciences IP playbook, creating new patterns of patent ownership, licensing and litigation and generating fresh legal questions.